Background Randomized controlled trials have demonstrated the benefits of sodium–
glucose cotransporter 2 inhibitors (SGLT2is) in people with type 2 diabetes mellitus (T2DM) …

Background We conducted a systematic review and meta-analysis of the cardiovascular,
kidney, and safety outcomes of sodium-glucose cotransporter 2 inhibitors (SGLT2i) among …

Background: Many studies have shown the effects of SGLT2 inhibitors on type 2 diabetes,
but the effects in patients with type 2 diabetes with chronic kidney disease remains unclear …

Background There were limited data on the efficacy and safety profile on use of sodium–
glucose co-transporter 2 receptor (SGLT2) inhibitors in diabetic patients with advanced …

Aim The use of sodium glucose co‐transporter 2 (SGLT2) inhibitors in patients with type 2
diabetes mellitus (T2DM) and chronic kidney disease (CKD) has been limited, primarily …

Background Sodium-glucose cotransporter 2 inhibitor (SGLT2i) should be considered for
patients with type 2 diabetes (T2D) and chronic kidney disease (CKD) having estimated …

OBJECTIVE Randomized controlled trials have shown kidney-protective effects of sodium–
glucose cotransporter 2 (SGLT2) inhibitors, and clinical practice databases have suggested …

Background A systematic review and meta-analysis was performed to assess the kidney and
cardiovascular (CV) outcomes of sodium-glucose cotransporter 2 (SGLT2) inhibitors in …

Background Sodium–glucose co-transporter 2 (SGLT2) inhibitors may have renal protective
effects in people with impaired kidney function. We assessed the use of SGLT2 inhibitors in …

Aim To conduct a systematic review of observational studies to explore the real‐world
kidney benefits of sodium‐glucose cotransporter‐2 (SGLT2) inhibitors in a large and diverse …